As a master cellular regulator and tumor suppressor, phosphatase and tensin homolog (PTEN) is frequently inactivated by mutation or gene deletion in human cancer [1] [2] [3] [4] . PTEN functions as a lipid phosphatase that negatively regulates the phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway, a key downstream mediator of the effects of most receptor tyrosine kinases (RTKs) 5 . PI3K activates signaling by catalyzing the formation of the lipid second messenger phosphatidyl inositol 3,4,5-trisphosphate (PIP3) 5 , whereas PTEN antagonizes signaling by dephosphorylating PIP3 (refs. 6-9).
a r t i c l e s
As a master cellular regulator and tumor suppressor, phosphatase and tensin homolog (PTEN) is frequently inactivated by mutation or gene deletion in human cancer [1] [2] [3] [4] . PTEN functions as a lipid phosphatase that negatively regulates the phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway, a key downstream mediator of the effects of most receptor tyrosine kinases (RTKs) 5 . PI3K activates signaling by catalyzing the formation of the lipid second messenger phosphatidyl inositol 3,4,5-trisphosphate (PIP3) 5 , whereas PTEN antagonizes signaling by dephosphorylating PIP3 (refs. 6-9) .
The protein tyrosine phosphatase activity of PTEN has also been suggested on the basis of its domain structure 10, 11 and the observation that PTEN can dephosphorylate synthetic phosphotyrosine peptides 11, 12 . Furthermore, it has been suggested that such protein phosphatase activity may be relevant to various functions of PTEN, such as cell migration and invasion [13] [14] [15] [16] . However, whether PTEN is a physiologically relevant protein phosphatase remains an open question.
The biological function of PTEN can be abrogated by defects in its post-translational regulation in addition to genetic mutation and deletion 3, 17, 18 . Previously, we discovered that PTEN is regulated by ubiquitination and is a substrate of the neural precursor cell-expressed developmentally downregulated protein 4 (NEDD4) ubiquitin ligase 19, 20 . However, under normal growth conditions, inhibition of NEDD4 expression does not affect cellular PTEN levels or AKT activation in several examined cell types 21 , thus suggesting that regulation of PTEN by NEDD4 might be relevant only under specific biological contexts. Indeed, under multiple specific biological conditions including neuronal branching and outgrowth 22, 23 , neuronal ischemic response 24 and T-cell activation 25 , NEDD4 suppresses PTEN function via ubiquitination and thus accomplishes proper biological outcomes. Further, regulation of PTEN by NEDD4 often involves additional factors such as the tyrosine kinase RAK 26 and the NEDD4 stimulators NDFIP1 and NDFIP2 (ref. 27) .
In this study, we sought to investigate whether signaling by insulin and IGF also requires NEDD4-mediated PTEN suppression because deletion of the Nedd4 gene in mice resulted in severe growth retardation 28 , a phenotype reminiscent of that observed in mice with deletion of AKT1 (refs. 29,30) , insulin-like growth factor 1 (IGF1) or IGF1 receptor (IGF1R) 31 . By conducting both cellular and in vitro biochemical analyses, we discovered that suppression of PTEN by NEDD4 has a physiologic role in maintaining AKT activation induced specifically by IGFs but not by other tested agonists. Consistently with this function, NEDD4 regulates IGF1R-dependent cancer cell growth and insulin-mediated glucose metabolism. Notably, we discovered that PTEN is a protein tyrosine phosphatase for IRS1, thus demonstrating the protein tyrosine phosphatase activity of PTEN in a physiologically relevant setting.
RESULTS

NEDD4 is required for signaling by IGF but not epidermal growth factor
We found that in NEDD4 −/− mouse embryonic fibroblasts (MEFs), compared to paired NEDD4 +/+ MEFs, activation of AKT phosphorylation in response to IGF1, IGF2 or insulin was greatly diminished, whereas induction of AKT phosphorylation by serum or epidermal growth factor (EGF) was intact in NEDD4 −/− MEFs ( Fig. 1a and Supplementary Fig. 1a) . Consistently with this, NEDD4 deletion did not abrogate EGF signaling in the presence of different doses of EGF to trigger the pathway (Supplementary Fig. 1b) . In all these experiments, cells were serum-starved for 3 h and then subjected to stimulation with the agonists for 5 min. To further confirm the effect of NEDD4 in IGF signaling, we engineered MEFs to express two different short hairpin RNA (shRNA) sequences against NEDD4 in a doxycycline (Dox)-inducible manner (Fig. 1b) . Dox caused marked reduction of NEDD4 expression and suppressed the ability of IGF1 to induce the phosphorylation of both AKT and IRS1.
We examined the kinetics of induction of signaling by IGF1, insulin and EGF in more detail (Fig. 1c,d and Supplementary Fig. 1c) . In wild-type (WT) MEFs, IGF1 rapidly induced the phosphorylation of IGF1R and IRS1, and this phosphorylation persisted without decline for at least 60 min. This was associated with a potent and equally persistent induction of AKT phosphorylation (Fig. 1c) . After Doxinduced NEDD4 knockdown, although IGF1R phosphorylation was unaffected, induction of IRS1 phosphorylation at Y608 5 min after IGF1 stimulation was substantially repressed and remained so up to 60 min later. This was accompanied by markedly reduced induction of AKT phosphorylation. Insulin signaling was similarly defective after NEDD4 knockdown (Supplementary Fig. 1c ). In contrast, NEDD4 knockdown had no effect on the magnitude or kinetics of the induction by EGF of phosphorylation of EGF receptor (EGFR) or AKT (Fig. 1d) . Thus, NEDD4 is specifically required for induction of the PI3K-AKT pathway by IGF and insulin but not by EGF or serum.
The role of NEDD4 in IGF signaling is PTEN dependent
In NEDD4-deficient cells, the ligand activation of IGF1R and insulin receptor, as monitored by the induction of their phosphorylation, was normal (Figs. 1c and 2a and Supplementary Fig. 1c ). For IGF1R, its early phosphorylation at the Y1135 and Y1136 sites and at the juxtamembrane Y980 site was not inhibited by NEDD4 deletion (Fig. 2a) . However, induction of phosphorylation of both IRS1 and AKT was defective when NEDD4 was eliminated (Figs. 1c and 2a and Supplementary Fig. 1c) . Because NEDD4 is a PTEN ubiquitin ligase, we examined whether the requirement of NEDD4 for signaling by IGF or insulin is due to its suppression of PTEN function. Indeed, when PTEN was knocked down in NEDD4 −/− MEFs by two different Dox-inducible shRNA constructs, IGF1-induced IRS1 phosphorylation and AKT phosphorylation were restored (Fig. 2b) . Moreover, expression of shRNA-resistant PTEN in the NEDD4 −/− MEFs consistently prevented rescue of IGF1-induced AKT activation by PTEN shRNA (Fig. 2c) . These data suggest that NEDD4 enables IGF signaling by suppressing PTEN function.
The rescue of activation of both AKT and IRS1 by PTEN ablation suggests that suppression of IGF signaling by PTEN may not be simply due to its lipid phosphatase activity. IRS1 phosphorylation is required for many of the downstream effects of activating IGF1 receptor 32 . To explore possible mechanisms by which PTEN regulates IRS1 phosphorylation in a NEDD4-sensitive manner, we tested whether PTEN interacts with IRS1. As shown by a coimmunoprecipitation experiment (Fig. 2d) , PTEN interacted with IRS1 in cells, and this interaction was blocked by overexpression of WT but not enzymatically inactive NEDD4, thus suggesting that NEDD4 blocks the interaction between PTEN and IRS1 through its E3 ligase activity. However, we did not observe changes in gross PTEN protein expression when NEDD4 expression was knocked down in MEFs or when cells were stimulated with IGF1 (Fig. 1c) . Therefore, the precise mechanism by a r t i c l e s npg a r t i c l e s which NEDD4 regulates PTEN in response to stimulation by IGF or insulin is not clear at this stage. One possibility is that only a small subpopulation of total PTEN is required to suppress IGF signaling and that NEDD4 selectively antagonizes this subfraction. In line with this possibility, it was recently reported that NEDD4 preferentially ubiquitinates membrane-localized PTEN and that PTEN ubiquitination is sufficient to suppress its phosphatase activity even in the absence of proteasomal degradation 33 .
PTEN is a protein tyrosine phosphatase for IRS1
PTEN is a physiological lipid (PIP3) phosphatase, but it may also possess protein phosphatase activity. Because PTEN can regulate IRS1 phosphorylation, we tested whether phosphorylated IRS1 (p-IRS1) is a direct substrate of PTEN. We generated purified recombinant WT PTEN protein, C124S PTEN mutant protein (CS), which is defective in total enzymatic activity, and G129E PTEN mutant protein (GE), which cannot dephosphorylate PIP3 but can still dephosphorylate synthetic peptides containing phosphotyrosine (Fig. 3a) . We confirmed by an in vitro assay that WT PTEN but not the CS or GE mutant can dephosphorylate PIP3 (Supplementary Fig. 2a ). We also validated this conclusion in cells: WT PTEN but not the CS or GE mutant inhibited EGF-induced AKT activation (Fig. 3b) . We then generated p-IRS1 substrate by overexpressing hemagglutinin (HA)-tagged IRS1 and HA-tagged IGF1R in HEK293T cells and subsequently treating the cells with IGF1 and isolating IRS1 substrates by immunoprecipitation. When the isolated IRS1 was incubated with recombinant PTEN, we observed dephosphorylation of IRS1 in a PTEN dosedependent manner, as monitored with a specific antibody against phosphorylated Y612 (pY612) of IRS1 (Fig. 3c) . This activity can be blocked by a general protein phosphatase-inhibitor cocktail (Y inhibitor). We found that dephosphorylation of IRS1 is a property of WT PTEN (Fig. 3c) and the GE mutant but not the CS mutant (Fig. 3d) . The IRS1 protein tyrosine phosphatase activity of PTEN was also detectable with the pY989-specific IRS1 antibody and a general phosphotyrosine antibody (Fig. 3d) . Importantly, in these experiments, we found that the protein phosphatase activity of PTEN is specific for p-IRS1 and that the phosphorylation status of IGF1R (at the Y1135, Y1136 and Y980 sites) is not affected by PTEN (Fig. 3c,d ). This result is consistent with our observation that loss of NEDD4 (Figs. 1c and 2a) . We also generated recombinant protein with a recently reported PTEN mutation (Supplementary Fig. 2b ), Y138L (denoted YL mutant), previously reported to possess lipid phosphatase but not protein phosphatase activity 34 . Indeed, the YL mutant could not dephosphorylate IRS1 in vitro (Supplementary Fig. 2c ). As reported, unlike the GE or CS mutants, the YL mutant did possess lipid phosphatase activity. However, its lipid phosphatase activity was considerably lower than that of WT PTEN (Supplementary Fig. 2d) .
Given the data showing that purified PTEN is an IRS1 phosphatase, we sought to determine whether PTEN also functions as a NEDD4-suppressed IRS1 phosphatase in cells. In cellular reconstitution experiments, we blocked IGF1 induction of IRS1 phosphorylation with Dox-inducible NEDD4 RNA interference (RNAi; as in Fig. 1b ) and restored IRS1 phosphorylation by knocking down PTEN expression (Fig. 4a) . We then reconstituted these cells by expressing RNAi-resistant WT PTEN (Fig. 4b,e and Supplementary Fig. 3a) or mutant PTEN (CS mutant, Fig. 4c,e and Supplementary Fig. 3a, or  GE mutant, Fig. 4d,e and Supplementary Fig. 3a) . After induction of NEDD4 RNAi with Dox, IGF1-induced phosphorylation of IRS1 and AKT was greatly reduced in the PTEN-RNAi cells in which WT or GE mutant PTEN was reexpressed but not in those in which CS mutant PTEN was reexpressed. These data demonstrate that PTEN acts as an IRS1 phosphatase in cells and that this activity is dependent on protein phosphatase activity but not PIP3 phosphatase activity of the enzyme. In these cells, the effect of PTEN on IGF-induced IRS1 phosphorylation was detectable by antibodies specific to both pY608 (Fig. 4) and pY989 sites (Supplementary Fig. 3b-e) of IRS1, results consistent with our in vitro observations (Fig. 3d) .
The result that the PIP3 phosphatase-defective GE mutant reduced IRS1 phosphorylation to the same extent as did WT PTEN (Fig. 4d and Supplementary Fig. 3e) indicates that the effect of PTEN on IRS1 phosphorylation is not likely to be through certain indirect feedback regulation caused by the change of downstream PIP3 level or AKT activity. To further rule out the possible feedback mechanisms caused by PIP3-AKT change, we performed similar experiments (as in Fig. 4) in the presence of a pharmacological inhibitor of PI3K (GDC0941). This inhibitor prevented IGF1-induced PIP3 generation, as demonstrated by the lack of downstream AKT activation, although the upstream phosphorylation of IGF1R or IRS1 was intact (Supplementary Fig. 3f ). In the presence of the inhibitor, Dox-induced NEDD4 RNAi ablated IGF1-induced IRS1 phosphorylation in PTEN-knockdown cells only when WT PTEN was reexpressed in the cells (Fig. 4f) but not in the absence of PTEN expression (Fig. 4g) . Because cellular PIP3 generation was inhibited in these experiments, the observed PTEN effect on IRS1 phosphorylation was not caused by cellular PIP3 levels or the PIP3 phosphatase activity of PTEN. Therefore, all the results (Figs. 2-4) support that PTEN is a protein phosphatase of IRS1 that acts directly on p-IRS1 in a NEDD4-regulated manner.
It should be noted that, in these cellular experiments, we used transient PTEN knockdown because, as we and others have previously demonstrated, a permanent PTEN loss can cause a marked decrease in IGF1R expression and thus deficiency of IGF signaling 35 , and AKT inhibition can increase IGF1R expression by relieving feedback inhibition of FOXO 36 . Both genetic deletion of PTEN and long-term, stable PTEN shRNA expression caused a decline in IGF1R levels. Fig. 4a,b) . Reexpression of WT but not CS or GE mutant PTEN also restored IGF1R expression in PTEN −/− MEFs but had no effect on EGFR levels (Supplementary Fig. 4c) . Consistently with such feedback regulation, stable knockdown of PTEN enhanced IRS1 phosphorylation only minimally in NEDD4 −/− MEFs, although it substantially restored IGF1-induced AKT activation, presumably by suppressing the PIP3 phosphatase activity of PTEN (Supplementary Fig. 4d ).
NEDD4 and the biological function of signaling by IGF or insulin
To investigate the impact of NEDD4 on the biological functions of signaling by IGF or insulin, we first asked whether the requirement of NEDD4 in signaling by IGF1 or insulin has any effect on cell growth. Some cancer cells require IGF1R activity for the maintenance of proliferation, including the Ewing's sarcoma cell line TC71 and the breast cancer cell line MCF7 (both PTEN positive). Using pharmacological inhibitors for IGF1R (OSI-906) and EGFR (erlotinib), we confirmed that IGF1R activity but not EGFR activity is required for maintaining AKT activation in these cells ( Fig. 5a and Supplementary Fig. 5a ). Consistently with this, RNAi knockdown of NEDD4 also blocked AKT activation in these cells ( Fig. 5b and Supplementary Fig. 5b ). By contrast, the nonsmall cell lung cancer cell line PC9 (PTEN positive), which contains an activating mutant of EGFR and is dependent on EGFR signaling but not IGF1R signaling (Fig. 5a) , and the breast cancer cell line MDA-MB-468 (PTEN negative), which is dependent on neither ( Supplementary  Fig. 5a ), do not require NEDD4 expression for AKT activation ( Fig. 5c and Supplementary Fig. 5b ). NEDD4 was also selectively required for the proliferation of TC71 cells. In the IGF1R-dependent TC71 cells, NEDD4 knockdown potently reduced cell proliferation, whereas in PC9 cells, NEDD4 knockdown had no discernible effect (Fig. 5d,e) . Because insulin signaling is a major physiological regulator of glucose metabolism, NEDD4 could also be involved in glucose metabolism. For this reason, we examined the effect of NEDD4 knockdown on insulin-regulated glucose metabolism in MEFs. As expected, elimination of NEDD4 by Dox-induced RNAi significantly reduced glucose uptake and associated lactate production (Fig. 6a,b) , whereas glutamine uptake and associated glutamate production were not affected (Fig. 6c,d) .
DISCUSSION
Taken together, our results revealed a new function of PTEN as a protein phosphatase for IRS1 as well as mechanisms underlying specific regulation of IGF signaling by PTEN and NEDD4 (model in Fig. 7) . First, there has been a long-standing debate concerning whether PTEN is a biologically relevant protein phosphatase, so our demonstration of the biochemical nature of PTEN as both a protein phosphatase and a lipid phosphatase is notable. Second, until now, the biochemical effects of PTEN in PI3K signaling have been completely ascribed to its lipid phosphatase activity. Through this work, we have now obtained evidence showing that PTEN is a protein phosphatase and that it downregulates PI3K signaling in at least two ways: generally by decreasing PIP3 levels and, in a manner specific to signaling by IGF or insulin, by dephosphorylating IRS1.
It has been reported that NEDD4 deficiency leads to internalization and degradation of IGF1R or insulin receptor, beginning several hours after agonist stimulation 28 . Although a NEDD4-regulated receptordesensitization mechanism may be in play at a later stage of signaling by IGF or insulin, it does not provide an explanation for the involvement of PTEN, especially its protein phosphatase activity, and it cannot account for the rapid inhibition of activation of IRS1 and AKT by NEDD4 elimination, as observed as early as 5 min after agonist stimulation (Figs. 1 and 4) . Further, NEDD4 elimination blocked activation of only IRS1 and AKT but not that of IGF1R or insulin receptor (Figs. 1 and 4 and Supplementary Fig. 1c) , thus indicating that even in the absence of NEDD4, receptors are available on the cell surface for activation by their agonists at early time points. Our finding that PTEN can function as a protein phosphatase for IRS1 in a NEDD4-regulated manner is consistent with all these observations. Intriguingly, in addition to PTEN, other protein phosphatases can also negatively regulate signaling by IGF or insulin. For example, TCPTP and PTP1B can inactivate insulin signaling by dephosphorylating insulin receptor, and PTP1B may also dephosphorylate IRS1 (refs. 37-39) . A comparison indicated that the in vitro IRS1 phosphatase activity of PTEN was about ten-fold lower than that of PTP1B and that, unlike PTEN, PTP1B could dephosphorylate both IRS1 and IGF1R (Supplementary Fig. 2e ). It is likely that in cells there might be additional regulatory mechanisms to enhance the enzymatic activity of PTEN toward IRS1. Further, how does the IRS1 phosphatase activity of PTEN coordinate with that of TCPTP and PTP1B, and do these protein phosphatases function differentially, for example, in a tissue-and/or context-specific manner? Understanding these questions will provide further insights into the mechanisms and biology of signaling by IGF and insulin.
This work is also conceptually relevant for general RTK signaling. Diverse growth factors function by activating their corresponding RTKs, which in turn stimulate a variety of downstream signaling programs, including those entrained by pathways involving phospholipase C, STAT phosphorylation, RAS and PI3K and AKT 40 . The variety of proliferative RTK pathways may provide differential nodes for regulation. However, the mechanisms that enable specificity of signaling through these pathways and allow specific receptors to mediate very different biological effects remain poorly understood. The observation that NEDD4 is specifically required for IGF signaling but not EGF signaling provides mechanistic insights into how various RTK pathways can be distinctively regulated even though they all function through common downstream effector molecules. Figure 7 The IGF but not the EGF signaling pathway is regulated by the NEDD4-PTEN circuitry. Upon signaling by IGF, the IRS1 protein phosphatase activity of PTEN is antagonized by NEDD4. This mechanism accounts for the specific requirement of NEDD4 in IGF signaling but not EGF signaling. The lipid phosphatase activity of PTEN downregulates both IGF and EGF signals.
npg a r t i c l e s
By antagonizing the protein phosphatase activity of PTEN, NEDD4 can contribute to the effects of insulin and IGFs on multiple important physiological processes, including growth, metabolism and glucose homeostasis 5 . Further, because NEDD4 has other protein substrates such as RNA polymerase II, Cbl-b and activated Cdc42-associated tyrosine kinase [41] [42] [43] [44] , this ubiquitin ligase may possess additional biological functions independent of signaling by PTEN, IGF or insulin. This work also raises many important questions for future study. It is likely that the intensity and duration of IGF signaling in different tissues will be achievable by tuning the expression and activity of the PTEN and NEDD4 enzymes. Also, NEDD4 may be specifically stimulated by signaling involving IGF or insulin but not other RTKs to neutralize the inhibitory activity of PTEN. Furthermore, regulation of IGF signal or insulin signal by PTEN and NEDD4 could have key roles in the pathophysiology of cancers (such as Ewing's sarcoma) and metabolic diseases (such as diabetes and obesity). Our finding warrants a systematic search and functional investigation of other cellular phosphoproteins, beyond IGF signaling pathways, that may be subject to regulation by the protein phosphatase activity of PTEN.
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Methods and any associated references are available in the online version of the paper. 
AUTHoR CoNTRIBUTIoNS
Y.S., N.R. and X.J. designed the study; Y.S., J.W. and J.C. performed the experiments; Y.S., S.C., N.R. and X.J. wrote the paper; and all authors were involved in data analysis and interpretation.
